Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.